Rubicon Buys Stake in Arinna Lifesciences

Mumbai, Apr 15 (PTI) Rubicon Research on Wednesday announced the acquisition of a majority stake in Arinna Lifesciences for Rs 175.92 crores from its current shareholders to enter the Indian CNS (central nervous system) formulations market.

This acquisition furthers Rubicon's strategy of leveraging its IP and chronic products portfolio to unlock growth in key markets, particularly in the CNS therapeutic category which has always been a core focus area for Rubicon, the Mumbai-headquartered company said in a statement.

Arinna's sales and distribution network provides Rubicon access to patients and prescribers in India for its differentiated offerings, including a strong pipeline of specialty products and drug-device combinations.


The purchase consideration was determined to be approximately Rs 175.92 crores for the secondary acquisition of an 85 per cent equity shareholding at a price of Rs 158.53 per share.

The transaction is expected to close within 30 days upon satisfaction of agreed conditions precedent, said the company adding that Arinna's founder Vivek Seth will retain a 15 per cent ownership interest and continue as Arinna's Managing Director.

"The past decade has demonstrated the effectiveness of Rubicon's playbook of R&D innovation, execution rigour, and impeccable compliance standards, which enabled us to scale our US revenues by over 32 times from FY15 to FY25 while delivering best-in-class return ratios. Arinna now provides us a launchpad for deploying this playbook in the Indian domestic formulations market," Rubicon Chief Executive Officer Parag Sancheti said.